Cargando…
No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
Autores principales: | Ferreira, João Pedro, Girerd, Nicolas, Rocca, Hans-Peter Brunner-La, Pellicori, Pierpaolo, Cleland, John G., Rossignol, Patrick, Zannad, Faiez |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576594/ https://www.ncbi.nlm.nih.gov/pubmed/34772647 http://dx.doi.org/10.1016/j.acvd.2021.10.003 |
Ejemplares similares
-
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
por: Verdonschot, Job A. J., et al.
Publicado: (2021) -
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial
por: Cleland, John G F, et al.
Publicado: (2020) -
Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial
por: Monzo, Luca, et al.
Publicado: (2022) -
Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank
por: Rastogi, Tripti, et al.
Publicado: (2022) -
Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives
por: Ferreira, João Pedro, et al.
Publicado: (2016)